CTOs on the Move


 
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.mylan.com
  • 1000 Mylan Boulevard
    Canonsburg, PA USA 15317
  • Phone: 724.514.1800

Executives

Name Title Contact Details
Matthew Smith
Global Executive Director - Cyber and Information Security Profile
Ramkumar Rayapureddy
Global Chief Information Officer Profile
Franklin Donahoe
Chief Information Security Officer Profile
Franklin Donahoe
Chief Information Security Officer Profile

Similar Companies

Sovereign Pharmaceuticals

Sovereign Pharmaceuticals is your ideal CDMO partner for your pharma product development, formulation, fill/finish, packaging & commercial manufacturing needs.

Kamada

Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.

Nutrishare Inc

Nutrishare Inc is a Elk Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RSP Nutrition

RSP Nutrition is a company that makes premium nutritional supplements that inspire customers to live healthy, active lifestyles and achieve their fitness goals.

ERT

ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.